Fei Xu

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Venues

NPJ breast cancer

Breast cancer (Dove Medical Press)

Drug design, development and therapy

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-Min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Weiwei Xiao, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Ge Zhang, Piyawan Tienchaiananda, Masahiro Oikawa, Zhong-Yu Yuan, Qian-Jun Chen
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial. Breast cancer (Dove Medical Press) 16 (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-Min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Weiwei Xiao, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Ge Zhang, Piyawan Tienchaiananda, Masahiro Oikawa, Zhong-Yu Yuan, Qian-Jun Chen
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial. Breast cancer (Dove Medical Press) 16 (2024)
Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shu-Sen Wang, Ruoxi Hong
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis. NPJ breast cancer 10 (1) (2024)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Danyang Zhou, Mei Li, Mohamed Hussein Yasin, Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shu-Sen Wang, Fei Xu
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu, Hong-Yun Zhao, Yang Zhang, Zhi-Qiang Wang, Miao-Zheng Qiu, Fei Xu, Qiu-Qiong Yu, Yi-Wu Du, Yan-Xia Shi, De-Sheng Wang, Feng-Hua Wang, Rui-Hua Xu
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors. Nature communications 13 (1) (2022)
Fang-Fang Duan, Chenge Song, Yuyu Ma, Kui-Kui Jiang, Fei Xu, Xiwen Bi, Jiajia Huang, Ruoxi Hong, Zhangzan Huang, Qianyi Lu, Zhongyu Yuan, Shusen Wang, Wen Xia
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus. Drug design, development and therapy 15 (2021)
Kaping Lee, Qiufan Zheng, Qianyi Lu, Fei Xu, Ge Qin, Qinglian Zhai, Ruoxi Hong, Miao Chen, Wuguo Deng, Shusen Wang
CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4. Signal transduction and targeted therapy 6 (1) (2021)

Fei Xu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Fei Xu